Current Report Filing (8-k)
November 29 2018 - 4:04PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November
29, 2018
DARÉ BIOSCIENCE, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-36395
|
|
20-4139823
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
3655 Nobel Drive, Suite 260
San Diego, CA 92122
(Address of Principal Executive Offices and Zip Code)
Registrants telephone number, including area code:
(858)
926-7655
Not Applicable
(Former
name or former address, if changed since last report.)
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or
Rule 12b-2 of
the Securities Exchange Act of
1934 (§240.12b-2 of
this chapter).
Emerging growth company ☒
If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☒
On November 29, 2018, Daré Bioscience, Inc. (Daré), issued a press release regarding the initiation of the content validity
study for its product candidate, Sildenafil Cream, 3.6%, a copy of which is filed as Exhibit 99.1 to this report and is incorporated herein by reference.
By filing this report, including the information in Exhibit 99.1 attached hereto, Daré makes no admission as to the materiality of any information in
this report. Exhibit 99.1 contains information that is intended to be considered in the context of Darés filings with the U.S. Securities and Exchange Commission (the SEC), including its Annual Report on Form
10-K
filed on March 28, 2018 (as amended by the Form
10-K/A
filed on April 30, 2018), Quarterly Reports on Form
10-Q
filed on
May 14, 2018, August 13, 2018 and November 13, 2018, and other public announcements that Daré makes, by press release or otherwise, from time to time. Daré undertakes no duty or obligation to publicly update or revise
the information contained in this report, although it may do so from time to time as it believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases, or through other
public disclosure.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
DARÉ BIOSCIENCE, INC.
|
|
|
|
|
Dated: November 29, 2018
|
|
|
|
By:
|
|
/s/ Sabrina Martucci Johnson
|
|
|
|
|
|
|
Name: Sabrina Martucci Johnson
|
|
|
|
|
|
|
Title: President and Chief Executive Officer
|
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Sep 2023 to Sep 2024